Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms

Autor(es)

Silote, Gabriela Pandini ^[1] ; Sartim, Ariandra ^[1] ; Sales, Amanda ^{[2, 1]} ; Eskelund, Amanda ^[3] ; Guimaraes, F. S. ^[2] ; Wegener, Gregers ^[3] ; Joca, Samia ^{[4, 1]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto FCFRP, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Sch Med Ribeirao Preto FMRP, Sao Paulo - Brazil

^[3] Aarhus Univ, Translat Neuropsychiat Unit, Dept Clin Med, Aarhus - Denmark

^[4] Aarhus Univ, Aarhus Inst Adv Studies, Aarhus - Denmark

• Tipo de documento: Artigo Científico
• Fonte: Journal of Chemical Neuroanatomy; v. 98, p. 104-116, JUL 2019.
• Citações Web of Science: 3

Resumo

Significant limitations with the currently available antidepressant treatment strategies have inspired research on finding new and more efficient drugs to treat depression. Cannabidiol (CBD) is a non-psychotomimetic component of Cannabis sativa, and emerges in this regard as a promising compound. In 2010, we were the first laboratory to demonstrate that CBD is effective in animal models of predictive of antidepressant effect, a finding now confirmed by several other groups. Recent evidence suggests that CBD promotes both a rapid and a sustained antidepressant effect in animal models. CBD has a complex pharmacology, with the ability to interact with multiple neurotransmitter systems involved in depression, including the serotonergic, glutamatergic, and endocannabinoid systems. Moreover, CBD induces cellular and molecular changes in brain regions related to depression neurobiology, such as increased Brain Derived Neurotrophic Factor (BDNF) levels and synaptogenesis in the medial prefrontal cortex, as well as it increases neurogenesis in the hippocampus. This review presents a comprehensive critical overview of the current literature related to the antidepressant effects of CBD, with focus at the possible mechanisms. Finally, challenges and perspectives for future research are discussed. (AU)

• Processo FAPESP: 12/17626-7 - Mecanismos celulares e moleculares envolvidos no papel de neurotransmissores atípicos em transtornos neuropsiquiátricos
• Beneficiário: Francisco Silveira Guimaraes
• Linha de fomento: Auxílio à Pesquisa - Temático